An Overview of the Management of Mansonellosis
| Autor: | Thuy-Huong Ta-Tang, Sérgio Luiz Bessa Luz, James Lee Crainey, José M. Rubio |
|---|---|
| Přispěvatelé: | National Council for Scientific and Technological Development (Brasil), Fundação de Amparo à Pesquisa do Estado do Amazonas (Brasil), Instituto de Salud Carlos III |
| Rok vydání: | 2021 |
| Předmět: |
030231 tropical medicine
Review Disease 03 medical and health sciences 0302 clinical medicine Environmental health parasitic diseases medicine Mansonella perstans 030212 general & internal medicine Mansonellosis Disease burden Lymphatic filariasis General Environmental Science Mansonella streptocerca doxycycline biology business.industry General Engineering medicine.disease biology.organism_classification Mansonella ozzardi Doxycycline Neglected tropical diseases General Earth and Planetary Sciences business Wolbachia Malaria |
| Zdroj: | Repisalud Instituto de Salud Carlos III (ISCIII) Research and Reports in Tropical Medicine |
| ISSN: | 1179-7282 |
| DOI: | 10.2147/rrtm.s274684 |
| Popis: | Mansonellosis is caused by three filarial parasite species from the genus Mansonella that commonly produce chronic human microfilaraemias: M. ozzardi, M. perstans and M. streptocerca. The disease is widespread in Africa, the Caribbean and South and Central America, and although it is typically asymptomatic it has been associated with mild pathologies including leg-chills, joint-pains, headaches, fevers, and corneal lesions. No robust mansonellosis disease burden estimates have yet been made and the impact the disease has on blood bank stocks and the monitoring of other filarial diseases is not thought to be of sufficient public health importance to justify dedicated disease management interventions. Mansonellosis´s Ceratopogonidae and Simuliidae vectors are not targeted by other control programmes and because of their small size and out-door biting habits are unlikely to be affected by interventions targeting other disease vectors like mosquitoes. The ivermectin and mebendazole-based mass drug administration (iMDA and mMDA) treatment regimens deployed by the WHO´s Elimination of Neglected Tropical Diseases (ESPEN) programme and its forerunners have, however, likely impacted significantly on the mansonellosis disease burden, principally by reducing the transmission of M. streptocerca in Africa. The increasingly popular plan of using iMDA to control malaria could also affect M. ozzardi parasite prevalence and transmission in Latin America in the future. However, a potentially far greater mansonellosis disease burden impact is likely to come from shortcourse curative anti-Wolbachia therapeutics, which are presently being developed for onchocerciasis and lymphatic filariasis treatment. Even if the WHO´s ESPEN programme does not choose to deploy these drugs in MDA interventions, they have the potential to dramatically increase the financial and logistical feasibility of effective mansonellosis management.There is, thus, now a fresh and urgent need to better characterise the disease burden and ecoepidemiology of mansonellosis so that effective management programmes can be designed, advocated for and implemented. We would like to express our special thanks to María Belén García Fernández for helping us to draw the life-cycle of Mansonella species. JLC and SLBL also gratefully acknowledge support from the Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM; 062.01282/2018 and 002.00200/2019). And JLC would like to acknowledge support he receives from a Conselho Nacional de Desenvolvimento Científica e Tecnológico (CNPq) productivity grant. THTT is funded by a Sara Borrell contract from the Instituto de Salud Carlos III. Sí |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|